Dynal Biotech bulks up in HLA (human lymphocyte antigen) with Pel-Freez buy
This article was originally published in Clinica
Oslo, Norway-based Dynal Biotech is to acquire a package of businesses of Pel-Freez giving it increased presence in the US human lymphocyte antigen (HLA) analysis market and a direct bridge into the Chinese market. The acquisition includes Pel-Freez Clinical Systems of Milwaukee, Wisconsin, Pel-Freez Biotechnology of Beijing, China, and other assets of Pel-Freez Diagnostics. It is scheduled to close at the end of October.